Our results suggest that Gnetin C may promote APN multimerization not only through activation of the PPARγ-DsbA-L-Ero-1α axis in adipose tissue but also indirectly via the Sirt1-FGF21 axis in the liver, highlighting its promise as a novel agent for metabolic disease therapy. Here, FGF21 is linked to metabolic disease.